India, Sept. 22 -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (CNSY), a CNS oncology company, announced that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan effective September 1, 2026, to provide the CNSide Cerebrospinal Fluid (CSF) Tumour Cell Enumeration (TCE) assay.
CNSide Diagnostics develops tests such as CNSide, designed to identify tumour cells that have metastasised to the central nervous system in patients with carcinomas and melanomas.
Specifically, the CNSide CSF Assay Platform enables quantitative analysis of cerebrospinal fluid to inform and improve the management of patients with leptomeningeal metastases.
Blue Cross Blue Shield of Michigan, along with Blue C...